Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20477865 | 0.85 | PDE2A (0.33) | — | |
| SCHEMBL20477853 | 0.82 | FFAR1 (0.30) | — | |
| SCHEMBL31052366 | 0.78 | GRM5 (0.35) | CTSK | |
| SCHEMBL2331971 | 0.78 | GRM5 (0.35) | CTSK | |
| SCHEMBL1535653 | 0.78 | TSHR (0.36) | POLB | |
| SCHEMBL8812553 | 0.78 | CYP2A6 (0.46) | — | |
| SCHEMBL1145967 | 0.77 | ALOX5AP (0.38) | ARALOX5APFEN1BRD4POLB | |
| SCHEMBL16808275 | 0.77 | NSD2 (0.39) | ARCHEK1 | |
| SCHEMBL4050106 | 0.76 | APP (0.35) | — | |
| SCHEMBL2462510 | 0.76 | CYP11B1 (0.36) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233969-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-9233969-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8835631-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835631-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2154135-B1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-2532658-A1 | Therapeutic agent for cerebral infarction | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20100179157-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2154135-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1B, IL1A | AR 4882/4885ALOX5AP 2069/4885FEN1 3931/4885 |
| US-20100179157-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | AR 4884/4885ALOX5AP 1814/4885FEN1 3967/4885 |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | AR 4884/4885ALOX5AP 1814/4885FEN1 3967/4885 |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | AR 4884/4885ALOX5AP 1814/4885FEN1 3967/4885 |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | AR 4884/4885ALOX5AP 1814/4885FEN1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.